Skip to content

Brain and Peripheral Electrical Stimulation in Chronic Low Back Pain: a Factorial Design

Treatment of Chronic Non-specific Low Back Pain With Brain and Peripheral Electrical Stimulation: a Factorial, Randomized Controlled Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01896453
Enrollment
92
Registered
2013-07-11
Start date
2013-06-30
Completion date
2014-12-31
Last updated
2014-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Brief summary

The purpose of this study is to evaluate the efficacy of brain and peripheral electrical stimulation on chronic non-specific low back pain patients.

Interventions

PROCEDURETranscranial direct current stimulation (tDCS)

Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively

PROCEDURETranscutaneous electrical nerve stimulation (TENS)

Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Males and females aged \> 18 years and \<65 years * Complaining of back pain for more than three months * Presence of a chronic pain measurable with the number rating scale (NRS 0-10) not less than 4 during a 1 week daily NRS monitoring * Seeking care for low back pain

Exclusion criteria

* Previous surgery on the spine, spondylolisthesis * Previous treatment with TENS \<6 months * Previous treatment with tDCS * Disc herniation with nerve compression * Neurological, psychiatric and rheumatologic diseases * Impaired sensibility * Use of pacemakers or other implanted devices * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Pain intensityFour weeks after randomizationPain intensity will be evaluated by numerical rating scale (0-10).

Secondary

MeasureTime frameDescription
Quality of pain4 weeks, 3 and 6 months after randomization.The Short form of the McGill pain questionnaire (SF-MPQ) consists of 15 representative words from the sensory and affective categories of the standard long form. The 6 point intensity scale and a VAS are included to provide indices of overall pain intensity.
Disability4 weeks, 3 and 6 months after randomization.The Roland Morris disability questionnaire (RMDQ) is composed of 24 yes or no questions designed to assess disability related to back pain.
Global perceived effect (GPE)4 weeks, 3 and 6 months after randomization.Global perceived effect is an 11 point scale that ranges from 5 (vastly worse) through 0 (no change) to 5 (completely recovered). For all measures of global perceived effect (at baseline and all follow-ups), participants were asked compared to when this episode first started, how would you describe your back these days. A higher score indicates higher recovery from the condition.
Pain intensity3 and 6 months after randomizationPain intensity will be evaluated by numerical rating scale (0-10)

Other

MeasureTime frameDescription
Satisfaction with care4 weeks after randomizationSatisfaction with care will be measured by the Medrisk Instrument for Measuring Patient Satisfaction with Physiotherapy Care.
Depression4 weeks, 3 and 6 months after randomizationBeck depression inventory (BDI) for depressive symptoms that we tracked as possible confounding factor.
Anxiety4 weeks, 3 and 6 months after randomization.Visual analogue scale (VAS)for anxiety assesses anxiety symptoms that we tracked as possible confounding factor.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026